Nvidia Corp.’s stock continued to bleed in the aftermath of last week’s earnings report. The stock has fallen in four of the six sessions since that report, and it saw especially heavy ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Nvidia Corp.’s last earnings call was one of the best that Melius Research analyst Ben Reitzes had ever heard. Can the ...

Nvidia Corp. is throwing off cash, and the company plans to return even more of that to investors. The semiconductor company announced alongside its earnings on Wednesday that it has boosted its ...

Nvidia (NASDAQ: NVDA) is at the epicenter of the artificial intelligence (AI) revolution. It designs the most powerful data center chips for AI development, and demand continues to outstrip supply ...

Ahead of its upcoming Q2 FY2025 report, Nvidia Corporation stock is experiencing significant volatility. While a double beat is likely, the sustainability of Nvidia's rapid growth and high margins ...

I am talking about Nvidia (NVDA). Earnings are out on Aug. 28 after the close of trading, and it could mean big things for the AI trade as Morning Brief co-host Seana Smith points out. Every day ...

Nvidia once again beat Wall Street’s expectations when it reported earnings on Wednesday. But for a company that’s been on a stunning growth streak over the past two years, merely great ...

NVS is a Zacks Rank #2 (Buy) stock, with a Momentum Style Score of A and VGM Score of B. Shares are down 0.2% over the past one week and up 0.9% over the past four weeks. NVS has gained 14.6% in ...

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...

Truist lowered the stock rating from Buy to Hold. Vandana Singh Novartis Wins FDA Approval of Kisqali for Early Breast Cancer Novartis (NYSE: NVS) announced that the FDA has approved breast cancer ...